Literature DB >> 33115722

Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation.

Ajit P Limaye1, Tara M Babu2,3, Michael Boeckh4,5.   

Abstract

Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS, transplant recipients, and fetuses, are at the highest risk for complications from cytomegalovirus (CMV) infection. Despite substantial progress in prevention, diagnostics, and treatment, CMV continues to negatively impact both solid-organ transplant (SOT) and hematologic cell transplant (HCT) recipients. In this article, we summarize important developments in the field over the past 10 years and highlight new approaches and remaining challenges to the optimal control of CMV infection and disease in transplant settings.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  antiviral agents; clinical trials; cytomegalovirus; diagnostics; immune monitoring; immunocompromised hosts; transplant infectious diseases; transplantation; vaccines

Year:  2020        PMID: 33115722      PMCID: PMC7920732          DOI: 10.1128/CMR.00043-19

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  271 in total

1.  Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients.

Authors:  A Humar; D Gregson; A M Caliendo; A McGeer; G Malkan; M Krajden; P Corey; P Greig; S Walmsley; G Levy; T Mazzulli
Journal:  Transplantation       Date:  1999-11-15       Impact factor: 4.939

2.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

Authors:  Karl S Peggs; Stephanie Verfuerth; Arnold Pizzey; Naeem Khan; Malcolm Guiver; Paul A Moss; Stephen Mackinnon
Journal:  Lancet       Date:  2003-10-25       Impact factor: 79.321

3.  The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.

Authors:  Lynn El Haddad; Ella Ariza-Heredia; Dimpy P Shah; Ying Jiang; Ted Blanchard; Shashank S Ghantoji; Firas El Chaer; Danielle El-Haddad; Amrita Prayag; Lior Nesher; Katy Rezvani; Elizabeth Shpall; Roy F Chemaly
Journal:  J Infect Dis       Date:  2019-02-23       Impact factor: 5.226

4.  Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.

Authors:  Barbara Withers; Emily Blyth; Leighton E Clancy; Agnes Yong; Chris Fraser; Jane Burgess; Renee Simms; Rebecca Brown; David Kliman; Ming-Celine Dubosq; David Bishop; Gaurav Sutrave; Chun Kei Kris Ma; Peter J Shaw; Kenneth P Micklethwaite; David J Gottlieb
Journal:  Blood Adv       Date:  2017-11-02

5.  Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.

Authors:  J Kobashigawa; H Ross; C Bara; J F Delgado; T Dengler; H B Lehmkuhl; S-S Wang; G Dong; S Witte; G Junge; L Potena
Journal:  Transpl Infect Dis       Date:  2012-09-26       Impact factor: 2.228

6.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

Review 7.  The Cell Biology of Cytomegalovirus: Implications for Transplantation.

Authors:  H Kaminski; J A Fishman
Journal:  Am J Transplant       Date:  2016-04-21       Impact factor: 8.086

8.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Authors:  Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

9.  Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.

Authors:  M Viganò; T Dengler; M F Mattei; A Poncelet; J Vanhaecke; E Vermes; R Kleinloog; Y Li; Y Gezahegen; J F Delgado
Journal:  Transpl Infect Dis       Date:  2009-09-09       Impact factor: 2.228

10.  Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients.

Authors:  Bradley J Gardiner; Natalie E Nierenberg; Jennifer K Chow; Robin Ruthazer; David M Kent; David R Snydman
Journal:  Clin Infect Dis       Date:  2018-10-15       Impact factor: 9.079

View more
  10 in total

1.  4,5-Dihydroxypyrimidine Methyl Carboxylates, Carboxylic Acids, and Carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.

Authors:  Tianyu He; Tiffany C Edwards; Jiashu Xie; Hideki Aihara; Robert J Geraghty; Zhengqiang Wang
Journal:  J Med Chem       Date:  2022-04-04       Impact factor: 8.039

Review 2.  Methods for Studying Endocytotic Pathways of Herpesvirus Encoded G Protein-Coupled Receptors.

Authors:  Maša Mavri; Katja Spiess; Mette Marie Rosenkilde; Catrin Sian Rutland; Milka Vrecl; Valentina Kubale
Journal:  Molecules       Date:  2020-12-03       Impact factor: 4.411

3.  Affinity Maturation of a T-Cell Receptor-Like Antibody Specific for a Cytomegalovirus pp65-Derived Peptide Presented by HLA-A*02:01.

Authors:  Se-Young Lee; Deok-Han Ko; Min-Jeong Son; Jeong-Ah Kim; Keunok Jung; Yong-Sung Kim
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

4.  Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease.

Authors:  Yu Akahoshi; Shun-Ichi Kimura; Yuma Tada; Toshihiro Matsukawa; Masaharu Tamaki; Noriko Doki; Naoyuki Uchida; Masatsugu Tanaka; Hirohisa Nakamae; Takuro Kuriyama; Ken-Ichi Matsuoka; Takashi Ikeda; Takafumi Kimura; Takahiro Fukuda; Yoshinobu Kanda; Yoshiko Atsuta; Makoto Murata; Seitaro Terakura; Hideki Nakasone
Journal:  Blood Adv       Date:  2022-01-25

5.  Cytomegalovirus Viral Load in Transplanted Patients Using the NeuMoDx™ (Qiagen) Automated System: A 1-Month Experience Feedback.

Authors:  Léa Luciani; Denis Mongin; Laetitia Ninove; Antoine Nougairède; Kevin Bardy; Céline Gazin; Remi N Charrel; Christine Zandotti
Journal:  Viruses       Date:  2021-08-16       Impact factor: 5.048

Review 6.  Laboratory diagnostic testing for cytomegalovirus infection in solid organ transplant patients.

Authors:  Hyeyoung Lee; Eun-Jee Oh
Journal:  Korean J Transplant       Date:  2022-03-31

7.  Human cytomegalovirus strain diversity and dynamics reveal the donor lung as a major contributor after transplantation.

Authors:  Büsra Külekci; Stefan Schwarz; Nadja Brait; Nicole Perkmann-Nagele; Peter Jaksch; Konrad Hoetzenecker; Elisabeth Puchhammer-Stöckl; Irene Goerzer
Journal:  Virus Evol       Date:  2022-08-24

8.  8-Hydroxy-1,6-naphthyridine-7-carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.

Authors:  Eunkyung Jung; Ryuichi Majima; Tiffany C Edwards; Ruben Soto-Acosta; Robert J Geraghty; Zhengqiang Wang
Journal:  ChemMedChem       Date:  2022-08-10       Impact factor: 3.540

Review 9.  Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Markus J Barten; Fausto Baldanti; Alexander Staus; Christian M Hüber; Kyriaki Glynou; Andreas Zuckermann
Journal:  Life (Basel)       Date:  2022-03-02

10.  Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.

Authors:  Sunwen Chou; Matthew Watters; Rohita Sinha; Steven Kleiboeker
Journal:  Antiviral Res       Date:  2021-07-14       Impact factor: 10.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.